Skip to main content
Fig. 6 | Clinical Epigenetics

Fig. 6

From: DNA methylation regulates TIGIT expression within the melanoma microenvironment, is prognostic for overall survival, and predicts progression-free survival in patients treated with anti-PD-1 immunotherapy

Fig. 6

Kaplan–Meier analysis of overall and progression-free survival in melanoma patients stratified according to TIGIT mRNA expression, CpG5 methylation, and TIGIT+ lymphocyte score. a Overall survival in melanoma patients stratified according to tumor TIGIT mRNA expression levels (TCGA cohort). b Overall survival in melanoma patients stratified according to tumor TIGIT methylation levels at CpG5 (TCGA cohort). c Progression-free survival in ICB treated melanoma patients stratified according to tumor TIGIT mRNA expression levels (Liu et al. cohort [42]). d, e Progression-free survival in ICB treated melanoma patients stratified according to tumor TIGIT methylation levels at CpG5 (d) and TIGIT+ lymphocyte score (e) (UKB ICB cohort). All P values refer to log-rank tests

Back to article page